| RESVERLOGIX CORP |
| Kanada |
| Gesundheit |
| CA76128M1086 / A0DP7L |
| RFS (Frankfurt) |
| FRA:RFS, ETR:RFS, RFS:GR |
| - |
| http://www.resverlogix.co.. |
|
Resverlogix Corp. is a biotechnology company primarily focused on developing therapeutics for the treatment of chronic diseases. Central to the company's research and development efforts is its lead drug candidate, designed to reduce the progression ..
>Volltext.. |
| 21.58 Mio. EUR |
| 85.29 Mio. EUR |
| - |
| -3.94 Mio. EUR |
| -6.24 Mio. EUR |
| -0.02 EUR |
| 63.76 Mio. EUR |
| 0.06 Mio. EUR |
| -3.16 Mio. EUR |
| - |
| - |
| 34.45% |
| - |
| - |
| - |
| - |
| RESVERLOGIX |
| 01.04.26 |
|